Elicio to advance pancreatic, HPV vaccines, CAR T booster with $33M B round

Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies.

Elicio Therapeutics’ Amphiphile platform, which attaches antigens to an

Read the full 430 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE